Get to know our clinical trials

Clinical trial of iberdomide, daratumumab and dexamethasone in patients with relapsed or refractory multiple myeloma.

THE OBJECTIVE OF THIS STUDY IS TO TEST THE EFFICACY OF AN INVESTIGATIONAL NEW DRUG, IBERDOMIDE (CC-220), TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHEN USED IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE.

Imagen Dr. Jesús San Miguel Izquierdo, Servicio de Hematología y Hemoterapia
Dr. Jesús San Miguel Curriculum
Specialist Haematology and Haemotherapy Department
Navarre headquarters
Madrid headquarters
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • PHASE 3 OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO COMPARE IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IBERDD) WITH DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MMRR). IMMUNOTHERAPY
  • Code EudraCT: 2020-000431-49
  • Protocol number: CC-220-MM-002
  • Promoter: Celgene Corporation

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION